News

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and body.
The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...
That's where a salicylic acid shampoo comes in. Like a dandruff shampoo, these formulas can help relieve dryness, flakes, and itchiness associated with the condition–but salicylic acid takes the scalp ...
Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...
evaluated the safety and efficacy of icotrokinra in 311 adults and adolescents 12 years of age and older with plaque psoriasis affecting the scalp, genital area, and/or palms of the hands and ...
Data from icotrokinra ICONIC-TOTAL show 66% of patients with scalp psoriasis and 77% with ... area as low as 1% and at least moderate plaque psoriasis (PsO) affecting high-impact skin sites.
Accessed May 2025. 7 Clinicaltrials. A study of JNJ-2113 for the treatment of participants with plaque psoriasis involving special areas (scalp, genital, and/or palms of the hands and the soles of ...
Findings indicated significantly higher rates of clinical improvement in scalp and body lesions among those receiving the active treatment compared to a placebo. Plaque psoriasis, a chronic ...
Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...
A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...
Plaque psoriasis is characterized by raised ... Scalp psoriasis shows up as itchy, scaly patches on the scalp that may bleed if you try to remove them. About half of people who have psoriasis ...